Fibroblast growth factor-23: What we know, what we don't know, and what we need to know

Nephrology Dialysis Transplantation

Volumn 28, Issue 9, 2013, Pages 2228-2236

  Kovesdy, Csaba P ^a,b,c   Quarles, Leigh Darryl ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Chronic kidney disease; FGF23; Outcomes; Physiology

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR;

ADVERSE OUTCOME; BONE METABOLISM; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; MINERAL METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

CHRONIC KIDNEY DISEASE; FGF23; OUTCOMES; PHYSIOLOGY;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884522131     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft065     Document Type: Review

References (102)

1. U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2010
2. Keith DS, Nichols GA, Gullion CM et al. Longitudinal followup and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
3. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745
4. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
5. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808
6. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007; 18: 304-311
7. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K et al. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006; 21: 1257-1262
8. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis 2007; 49: 581-591
9. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
10. Wanner C, Krane V, Marz Wet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
11. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 2010; 73: 268-275
12. Schwarz S, Trivedi BK, Kalantar-Zadeh K et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 825-831
13. Kovesdy CP, Kuchmak O, Lu JL et al. Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 468-476
14. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008; 73: 1296-1302
15. Kovesdy CP, Ureche V, Lu JL et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 25: 3003-3011
16. Moe SM, Drueke T, Lameire N et al. Chronic kidney diseasemineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14: 3-12
17. Bricker NS. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med 1972; 286: 1093-1099
18. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131-155
19. Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012; 318: 1040-1048
20. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118: 3820-3828
21. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
22. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
23. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
24. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
25. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. J Am Soc Nephrol 2011; 22: 1913-1922
26. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
27. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-569
28. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16: 107-137
29. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-197
30. Harmer NJ, Pellegrini L, Chirgadze D et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43: 629-640
31. Goetz R, Ohnishi M, Kir S et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012; 287: 29134-29146
32. Zhang X, Ibrahimi OA, Olsen SK et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-15700
33. Kuro OM, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51
34. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
35. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-1647
36. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315
37. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688
38. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889
39. Rhee Y, Bivi N, Farrow E et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011; 49: 636-643
40. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487
41. Saji F, Shigematsu T, Sakaguchi T et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299: F1212-F1217
42. Tsuji K, Maeda T, Kawane T et al. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 2010; 25: 1711-1723
43. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
44. Nishida Y, Taketani Y, Yamanaka-Okumura H et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006; 70: 2141-2147
45. Isakova T, Gutierrez OM, Smith K et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591
46. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149
47. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196
48. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524
49. Perwad F, Azam N, Zhang MY et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146: 5358-5364
50. Vervloet MG, van Ittersum FJ, Buttler RM et al. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011; 6: 383-389
51. Moe SM, Zidehsarai MP, Chambers MA et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 257-264
52. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278: 37419-37426
53. Goetz R, Nakada Y, Hu MC et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 2010; 107: 407-412
54. Smith ER, Ford ML, Tomlinson LA et al. Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta 2011; 412: 1008-1011
55. Jonsson KB. The role of fibroblast growth factor 23 in renal disease. Nephrol Dial Transplant 2005; 20: 479-482
56. Kuro O.M. Klotho in health and disease. Curr Opin Nephrol Hypertens 2012; 21: 362-368
57. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178
58. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218
59. Dai B, David V, Martin A et al. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model. PLoS One 2012; 7: e44161
60. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
61. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18: 1227-1234
62. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585
63. Pereira RC, Juppner H, Azucena-Serrano CE et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161-1168
64. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966
65. Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648
66. Arnlov J, Carlsson AC, Sundstrom J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83: 160-166
67. Khan AM, Chirinos JA, Litt H et al. FGF-23 and the Progression of Coronary Arterial Calcification in Patients New to Dialysis. Clin J Am Soc Nephrol 2012; 7: 2017-2022
68. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
69. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-551
70. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
71. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337: 116-122
72. Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688-2696
73. Kirkpantur A, Balci M, Gurbuz OA et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011; 26: 1346-1354
74. Canziani ME, Tomiyama C, Higa A et al. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011; 31: 26-32
75. Stevens KK, McQuarrie EP, Sands W et al. Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation. Int J Nephrol 2011; 2011: 297070
76. Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390
77. Mendoza JM, Isakova T, Ricardo AC et al. Fibroblast Growth Factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7: 1155-1162
78. Melamed ML, Michos ED, Post W et al. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637
79. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983
80. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013
81. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403
82. de Borst MH, Vervloet MG, ter Wee PM et al. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1603-1609
83. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73: 1355-1363
84. Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol 2003; 10: 184-196
85. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865
86. Zoccali C, Ruggenenti P, Perna A et al. Phosphate may promote ckd progression and attenuate renoprotective effect of ace inhibition. J Am Soc Nephrol 2011; 22: 1923-1930
87. Kalantar-Zadeh K, Kopple JD, Humphreys MH et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1507-1519
88. Stenvinkel P, Lindholm B, Heimburger M et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15: 1624-1630
89. Noori N, Sims JJ, Kopple JD et al. Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iran J Kidney Dis 2010; 4: 89-100
90. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339
91. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291
92. Yilmaz MI, Sonmez A, Saglam M et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012; 59: 177-185
93. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571
94. Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315-F1322
95. Kovesdy CP. Survival benefits with vitamin D receptor activation: new insights since 2003. Clin J Am Soc Nephrol 2010; 5: 1704-1709
96. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116
97. Koizumi M, Komaba H, Nakanishi S et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012; 27: 784-790
98. Chertow GM, Block GA, Correa-Rotter R et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
99. Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs 2008; 17: 451-467
100. Wohrle S, Henninger C, Bonny O et al. Pharmacological inhibition of FGFR signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 2012. doi: 10.1002/jbmr.1810. [Epub ahead of print]
101. Aono Y, Yamazaki Y, Yasutake J et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009; 24: 1879-1888
102. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553